Kathleen Farren - Merus BV IR Officer

Merus BV Management Efficiency

The company has return on total asset (ROA) of (0.216) % which means that it has lost $0.216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.446) %, meaning that it created substantial loss on money invested by shareholders. Merus BV's management efficiency ratios could be used to measure how well Merus BV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2024. Return On Capital Employed is likely to gain to -0.38 in 2024. At this time, Merus BV's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 94.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 4.8 M in 2024.

Similar Executives

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Merus NV is traded on NASDAQ Exchange in the United States. Merus BV (MRUS) is traded on NASDAQ Exchange in USA. It is located in Uppsalalaan 17, Utrecht, Netherlands, 3584 CT and employs 172 people. Merus BV is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Merus BV Leadership Team

Merus Stock Performance Indicators

Additional Tools for Merus Stock Analysis